CV Trial Interim Data Disclosures Need FDA Guidance, Stakeholders Say
Executive Summary
Possible approaches to keeping interim results confidential include limiting disclosure to a group of “firewalled” employees or having a Data Monitoring Committee notify FDA and/or the sponsor that a threshold level of cardiovascular risk has been excluded, without further details.